Noxopharm confirms NOX66 as non-toxic

Company News

by Jessica Amir

Noxopharm Limited (ASX:NOX) has received a green light to proceed with the recruitment of more patients for its anti-cancer drug, NOX66.

It comes as the cancer treatment company received clearance from its Data Safety Monitoring Committee that the drug was non-toxic.

The review of the first group of patients found that after 14 continuous days of NOX66, there were no untoward side-effects.

The trial is on patients with late-stage breast, lung, ovary, prostate and head and neck cancers, who stopped responding to chemotherapy.

The company has now started phase 1b of the combination treatment .

Shares in Noxopharm Limited (ASX:NOX) are trading 2.56 per cent lower to 38 cents.
 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?